vs
Axsome Therapeutics, Inc.（AXSM）与Ribbon Communications Inc.（RBBN）财务数据对比。点击上方公司名可切换其他公司
Axsome Therapeutics, Inc.的季度营收约是Ribbon Communications Inc.的1.2倍（$191.2M vs $162.6M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs -10.3%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs -8.1%）
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
睿宾通信公司（Ribbon Communications Inc.）主要为电信运营商、企业及关键基础设施领域提供软件、IP与光网络解决方案。公司于2017年由Genband与Sonus Networks合并成立，总部位于美国得克萨斯州普莱诺，是一家上市科技企业。
AXSM vs RBBN — 直观对比
营收规模更大
AXSM
是对方的1.2倍
$162.6M
营收增速更快
AXSM
高出67.7%
-10.3%
两年增速更快
AXSM
近两年复合增速
-8.1%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $191.2M | $162.6M |
| 净利润 | — | $89.1M |
| 毛利率 | — | 42.9% |
| 营业利润率 | -33.1% | 37.6% |
| 净利率 | — | 54.8% |
| 营收同比 | 57.4% | -10.3% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXSMRBBN
| Q1 26 | $191.2M | $162.6M | ||
| Q4 25 | $196.0M | $227.3M | ||
| Q3 25 | $171.0M | $215.4M | ||
| Q2 25 | $150.0M | $220.6M | ||
| Q1 25 | $121.5M | $181.3M | ||
| Q4 24 | $118.8M | $251.4M | ||
| Q3 24 | $104.8M | $210.2M | ||
| Q2 24 | $87.2M | $192.6M |
净利润AXSMRBBN
| Q1 26 | — | $89.1M | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-12.1M | ||
| Q2 25 | $-48.0M | $-11.1M | ||
| Q1 25 | $-59.4M | $-26.2M | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | $-13.4M | ||
| Q2 24 | $-79.3M | $-16.8M |
毛利率AXSMRBBN
| Q1 26 | — | 42.9% | ||
| Q4 25 | — | 53.3% | ||
| Q3 25 | — | 50.1% | ||
| Q2 25 | — | 49.6% | ||
| Q1 25 | — | 45.4% | ||
| Q4 24 | — | 55.7% | ||
| Q3 24 | — | 52.1% | ||
| Q2 24 | — | 50.8% |
营业利润率AXSMRBBN
| Q1 26 | -33.1% | 37.6% | ||
| Q4 25 | -13.8% | 4.1% | ||
| Q3 25 | -27.0% | 1.3% | ||
| Q2 25 | -24.5% | 1.9% | ||
| Q1 25 | -46.9% | -10.8% | ||
| Q4 24 | -61.1% | 13.2% | ||
| Q3 24 | -59.8% | -0.4% | ||
| Q2 24 | -89.5% | -1.0% |
净利率AXSMRBBN
| Q1 26 | — | 54.8% | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -5.6% | ||
| Q2 25 | -32.0% | -5.0% | ||
| Q1 25 | -48.9% | -14.5% | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | -6.4% | ||
| Q2 24 | -91.0% | -8.7% |
每股收益（稀释后）AXSMRBBN
| Q1 26 | — | $0.50 | ||
| Q4 25 | $-0.55 | $0.50 | ||
| Q3 25 | $-0.94 | $-0.07 | ||
| Q2 25 | $-0.97 | $-0.06 | ||
| Q1 25 | $-1.22 | $-0.15 | ||
| Q4 24 | $-1.54 | $0.05 | ||
| Q3 24 | $-1.34 | $-0.08 | ||
| Q2 24 | $-1.67 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $305.1M | $67.6M |
| 总债务越低越好 | $70.0M | — |
| 股东权益账面价值 | — | $419.1M |
| 总资产 | $713.6M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AXSMRBBN
| Q1 26 | $305.1M | $67.6M | ||
| Q4 25 | $322.9M | $96.4M | ||
| Q3 25 | $325.3M | $74.8M | ||
| Q2 25 | $303.0M | $60.5M | ||
| Q1 25 | $300.9M | $71.2M | ||
| Q4 24 | $315.4M | $87.8M | ||
| Q3 24 | $327.3M | $37.2M | ||
| Q2 24 | $315.7M | $64.6M |
总债务AXSMRBBN
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $342.1M | ||
| Q3 25 | — | $344.3M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $347.4M | ||
| Q4 24 | — | $348.3M | ||
| Q3 24 | — | $349.1M | ||
| Q2 24 | — | $350.0M |
股东权益AXSMRBBN
| Q1 26 | — | $419.1M | ||
| Q4 25 | $88.3M | $449.0M | ||
| Q3 25 | $73.7M | $360.1M | ||
| Q2 25 | $73.1M | $370.4M | ||
| Q1 25 | $53.2M | $381.8M | ||
| Q4 24 | $57.0M | $404.6M | ||
| Q3 24 | $92.9M | $395.5M | ||
| Q2 24 | $102.9M | $405.0M |
总资产AXSMRBBN
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $1.2B | ||
| Q3 25 | $669.3M | $1.1B | ||
| Q2 25 | $639.8M | $1.1B | ||
| Q1 25 | $596.7M | $1.1B | ||
| Q4 24 | $568.5M | $1.2B | ||
| Q3 24 | $561.5M | $1.1B | ||
| Q2 24 | $548.2M | $1.1B |
负债/权益比AXSMRBBN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.94× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | 0.86× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
RBBN
| Service | $94.5M | 58% |
| Product | $68.1M | 42% |
